SlideShare a Scribd company logo
1 of 1
Download to read offline
MerckMillipore.com
The life science business of Merck operates as
MilliporeSigma in the U.S. and Canada.
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9
VCD,e6cells/mL
Culture Age, days
ATF-6, 20 L
ATF-6, 40 L
Cellicon TFF,
50 L (1)
Cellicon TFF,
50 L (2)
Cellicon™
TFF Filter,
50 L (1)
Cellicon™
TFF Filter,
50 L (2)
0
50
100
150
200
0
5
10
15
20
0 1 2 3 4 5 6 7 8 9 10
kLa,hr-1
Measuredin1XPBS,55W/m3
Total Gas Flow, L / min
ActualVCD(e6c/mL)
ModeledMaxVCD(e6c/mL)
model-predicted max
VCD capability with this
cell line ~150 e6 c/mL
OUR = OTR
VCD x qO2 = kLa x (C* - CL)
Introduction
With recent advancements in media development and cell
retention technologies, perfusion processes are rapidly
emerging as a viable means to successfully intensify
upstream biomanufacturing operations. The fresh supply of
key nutrients coupled with the removal of waste products
while retaining the thriving cell culture in the bioreactor can
lead to higher accumulated cell densities, improved
viabilities, and greater volumetric productivities. These
process advancements can translate to savings in time,
footprint, and/or cost in the manufacturing space. In this
poster we explore key elements of the bioreactor design and
automation strategies that enable the successful
implementation of seed train intensification via perfusion.
Sparger performance characterization, cell retention device
connection, and evaluation of the Hamilton® Incyte viable cell
density (or permittivity) sensor are specifically explored. Cell
culture case studies are also presented to demonstrate the
effectiveness of using the Mobius® single-use bioreactor for
intensified seed train applications.
Perfused N-1 CoGS
Assessment
A comprehensive cost modeling assessment was performed
to examine more closely how specific production scenarios
can be impacted by implementing a perfused N-1 process
step followed by a fed-batch N (production). Figure 1 below
highlights a subset of the data generated.
Figure 1 Assumptions:
• 1 Seed Train - 1 Production bioreactor - 1 DSP
• 200 L N-1 bioreactor
• 2000 L Production bioreactor (X0=5 x106 cells/mL)
• 14 day production for both traditional and high seed
• Industry average costs
Figure 1:
CoGS, throughput, and batches/year are compared for
various scenarios of increasing production titer. The increase
in titer results when a perfused N-1 process enables a high-
seed fed-batch production. Four of the five scenarios
assume the production is carried out for a comparable
number of days compared to the traditional fed-batch
process (14 days), and a fifth scenario (bar 2) examines the
impact of perfused N-1 enabling a high-seed production
reactor to achieve comparable titer to the traditional process
but within a shorter duration of 10 days. For more
information watch the on demand webinar: A Cost Analysis
and Evaluation of Perfused Seed Train Scenarios Through
Process Modeling
Anne Hansen, Allyson Fournier, Alison Dupont, Marisa Maher, Hiral Gami, Habib Horry, Jeffrey Barna, Arshan Nazempour, Amy Wood
Merck
Hamilton® Incyte VCD Sensor
Exploration
The capability to incorporate new sensor technology such as viable cell
density (or permittivity) into recipes and PID control loops may help to
advance perfusion processing operations. Figures 5, 6 and 7 explore
how a VCD sensor can be used in perfusion processes in the Mobius®
single-use bioreactors.
Figures 5 & 6:
Offline VCD data is plotted with InCyte sensor permittivity data for the
growth phase of 4x 3L and 2x 50 L trials (Figure 5, top). When
plotted on an x-y scatter, the slope of the linear fit line gives a cell
factor of 1.45 (Figure 6, bottom). Using the offset value from the cell
free media “zero” prior to inoculation, the 1.45 cell factor was applied
retrospectively to the data collected during the 2nd 50 L trial, and
plotted as InCyte VCD in Figures 5 and 7 below. This historical
correlation model, using a single cell factor, showed strong correlation
between offline and inline VCD.
Figure 7:
Implementing CSPR control (cell specific perfusion rate, purple) during
a 50 L N-1 perfusion process using the Hamilton® InCyte VCD Sensor
provided a steady ratio of nutrients to cells, drove towards more
consistent cell culture conditions, and enabled a better estimate of
media usage. Note, CSPR control was not implemented until the
second day of perfusion (day 4 of process), due to the limited ability
for the pump to operate in a continuous mode at low speeds.
Operating the harvest pump in on/off mode is not recommended due
to potential negative impact on CRD performance.
Cell Culture & Sparger Performance Results
• 4 N-1 perfusion trials were performed with ring sparger
prototype flexware; 2 with Xcell™ ATF devices, 2 with
prototype Cellicon™ 50 L filters (operating in TFF mode)
• The 4 processes demonstrate consistent capability to support
VCDs of at least 50-90 e6 c/mL with the ring sparger
• Using the real-time gas flow rates and corresponding VCD
data from a cell culture trial, the specific oxygen uptake rate,
qO2, can be calculated. Together with measured kLa, the
maximum VCD that the system can support can be modeled.
In the example shown in Figure 4, using pure O2 and 55
W/m3, the system is expected to be able to support
sustaining up to 150 e6 c/mL with this cell line
Exploring Intensified Seed Train
Through Advancements in Perfusion
Processing Technologies
© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, Millipore, Cellicon, Mobius and
the vibrant M are trademarks, and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All
other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly
accessible resources. Lit. No. MK_PS6000EN V.1.0
Incyte VCD Sensor Exploration Results
• As shown in the 2nd 50 L trial in Figures 5 and 7, the offline
VCD had a strong correlation to the InCyte sensor VCD
during the growth phase of this process when using the
historical correlation model.
• This approach was successful during the growth phase of a
culture up to ~ 50 e6 c/mL
• Adjustments to the cell factor are likely to be needed to
maintain a strong correlation if higher densities and/or
subsequent culture phases occur in the process.
0
20
40
60
80
100
120
140
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6
HarvestRate,L/day
VCD,e6cells/mL
Weight,kg
CSPR,pL/cell.day
Culture Age, Days
InCyte VCD
Offline VCD
y = 1,4479x - 0,7763
R² = 0,9773
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70
e6cells/mL
pF/cm
Offline VCD
Linear
(Offline VCD)
0
10
20
30
40
50
60
70
80
90
100
3456789 01234567 12345 2345678 012345 0123456
pF/cm
e6cells/mL
Culture Age, days
Permittivity
(pF/cm)
Offline VCD
InCyte VCD
50L Trials3L Trials
4
5
NEW: entirely flexible film
construction @ bag base
NEW: 2 x ¾” AseptiQuik®
Connectors to install cell
retention technologies
2
NEW: Ability to include CO2 sensor
with control loop and use additional
spare sensor in PID control loops (ex:
Capacitance / VCD sensor for cell
bleed or CSPR control)
1
NEW: Built-in X-baffle;
promotes homogeneous mixing
and consistency across scales
5
4
6 NEW: load cell control loop
3 NEW: Ring sparger option
• Implementing a perfused N-1 operation can directly
translate to an improvement in throughput and/or
reduction in CoGS
• Decreased process duration, made possible by
perfused seed train operations, allows for more
batches per year
• Development of a high-seed fed-batch production
process, enabled by the perfused N-1 operation, is a
potential way to improve overall titer, drive down
costs, and improve throughput without the need of
additional batches or volume capacity
• Perfusion seed train operations can prove to be an
effective method of process intensification, while
keeping the production bioreactor operating in fed-
batch mode
CoGS Assessment Results
Bioreactor Advancements
Supporting Perfusion
Several upgrades have been made to the 50 and 200 L Mobius®
single-use bioreactors in order to meet the needs of perfused N-1
processes; refer to Figure 2 below.
Figure 2:
Key features in Mobius® 50 and 200 L single-use bioreactors
targeted to support perfused N-1 processes
Cell Culture and Sparger
Performance Results
Four N-1 perfusion process trials were conducted in prototype
flexware bags containing the ring sparger to assess performance.
Both ATF and TFF type CRDs were used.
Figure 3:
Several trials confirm that the Mobius® bioreactor system is capable
of supporting upwards of 50 e6 c/mL, with a max of 90 e6 c/mL
realized using a 50 L prototype of the Cellicon™ TFF filter (green).
Although the ring sparger was used in all 4 cases, two different cell
lines were used and process conditions were varied by design,
therefore identical performance was not expected across the trials.
Figure 4:
A model predicted capability to support a max VCD of 150 e6 c/mL
(pink) was determined based on measured kLa (purple), real-time
gas profiles (not shown), and VCD obtained during trial (blue)

More Related Content

What's hot

Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsNational Institute of Biologics
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesKBI Biopharma
 
Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...
Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...
Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...Merck Life Sciences
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...fujifilmdiosynth
 
Learn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigmaLearn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigmaMilliporeSigma
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMerck Life Sciences
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...MilliporeSigma
 
Long Acting Injectables - A New Dimension for Proteins and Peptides
Long Acting Injectables - A New Dimension for Proteins and PeptidesLong Acting Injectables - A New Dimension for Proteins and Peptides
Long Acting Injectables - A New Dimension for Proteins and PeptidesMerck Life Sciences
 
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...KBI Biopharma
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMilliporeSigma
 
Next Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein ManufacturingNext Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein ManufacturingKBI Biopharma
 
Get Proactive With Your Stability Program
Get Proactive With Your Stability ProgramGet Proactive With Your Stability Program
Get Proactive With Your Stability ProgramMerck Life Sciences
 
Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...MilliporeSigma
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up MilliporeSigma
 
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Merck Life Sciences
 
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...Merck Life Sciences
 
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...KBI Biopharma
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...MilliporeSigma
 
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...Merck Life Sciences
 
Managing Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a MoleculeManaging Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a MoleculeKBI Biopharma
 

What's hot (20)

Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applications
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
 
Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...
Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...
Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
 
Learn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigmaLearn about the latest innovations at MilliporeSigma
Learn about the latest innovations at MilliporeSigma
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
 
Long Acting Injectables - A New Dimension for Proteins and Peptides
Long Acting Injectables - A New Dimension for Proteins and PeptidesLong Acting Injectables - A New Dimension for Proteins and Peptides
Long Acting Injectables - A New Dimension for Proteins and Peptides
 
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Next Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein ManufacturingNext Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein Manufacturing
 
Get Proactive With Your Stability Program
Get Proactive With Your Stability ProgramGet Proactive With Your Stability Program
Get Proactive With Your Stability Program
 
Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
 
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
 
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
 
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...
 
Managing Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a MoleculeManaging Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a Molecule
 

Similar to Exploring Intensified Seed Train Through Advancements in Perfusion Processing Technologies

The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformMilliporeSigma
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformMerck Life Sciences
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMerck Life Sciences
 
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...KBI Biopharma
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Merck Life Sciences
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMerck Life Sciences
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMilliporeSigma
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppthirbogeremew2
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...Merck Life Sciences
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...MilliporeSigma
 
Single-Use-Bioreactors-A-Comprehensive-Examination.pptx
Single-Use-Bioreactors-A-Comprehensive-Examination.pptxSingle-Use-Bioreactors-A-Comprehensive-Examination.pptx
Single-Use-Bioreactors-A-Comprehensive-Examination.pptxtinatarariyan
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMerck Life Sciences
 
Cell Culture Company - FY22 Overview
Cell Culture Company - FY22 OverviewCell Culture Company - FY22 Overview
Cell Culture Company - FY22 OverviewRebeccaThompson802594
 
ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...
ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...
ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...IanTaylor50
 
Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line Stavros Theocharidis
 
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...KBI Biopharma
 
COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURING
COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURINGCOMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURING
COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURINGiQHub
 
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...KBI Biopharma
 

Similar to Exploring Intensified Seed Train Through Advancements in Perfusion Processing Technologies (20)

The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train Intensification
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train Intensification
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppt
 
High-performing CHO cell lines
High-performing CHO cell lines High-performing CHO cell lines
High-performing CHO cell lines
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
 
Single-Use-Bioreactors-A-Comprehensive-Examination.pptx
Single-Use-Bioreactors-A-Comprehensive-Examination.pptxSingle-Use-Bioreactors-A-Comprehensive-Examination.pptx
Single-Use-Bioreactors-A-Comprehensive-Examination.pptx
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
Cell Culture Company - FY22 Overview
Cell Culture Company - FY22 OverviewCell Culture Company - FY22 Overview
Cell Culture Company - FY22 Overview
 
Cell line development services
Cell line development servicesCell line development services
Cell line development services
 
ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...
ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...
ESACT 2017 Poster - A new cell line development platform for sigh efficiency ...
 
Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line
 
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
Integration of Cell Line and Process Development to Expedite Delivery of Bisp...
 
COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURING
COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURINGCOMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURING
COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURING
 
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
 

More from Merck Life Sciences

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeMerck Life Sciences
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsMerck Life Sciences
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesMerck Life Sciences
 

More from Merck Life Sciences (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 

Recently uploaded

Low Rate Call Girls In Bommanahalli Just Call 7001305949
Low Rate Call Girls In Bommanahalli Just Call 7001305949Low Rate Call Girls In Bommanahalli Just Call 7001305949
Low Rate Call Girls In Bommanahalli Just Call 7001305949ps5894268
 
Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...delhimodelshub1
 
VIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service Hyderabad
VIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service HyderabadVIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service Hyderabad
VIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service Hyderabaddelhimodelshub1
 
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...Call Girls Noida
 
Call Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service Mohali
Call Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service MohaliCall Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service Mohali
Call Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service MohaliHigh Profile Call Girls Chandigarh Aarushi
 
Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...delhimodelshub1
 
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...ggsonu500
 
Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...
Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...
Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...delhimodelshub1
 
Russian Call Girls in Raipur 9873940964 Book Hot And Sexy Girls
Russian Call Girls in Raipur 9873940964 Book Hot And Sexy GirlsRussian Call Girls in Raipur 9873940964 Book Hot And Sexy Girls
Russian Call Girls in Raipur 9873940964 Book Hot And Sexy Girlsddev2574
 
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012Call Girls Service Gurgaon
 
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591adityaroy0215
 
hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...
hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...
hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...delhimodelshub1
 
Call Girls Secunderabad 7001305949 all area service COD available Any Time
Call Girls Secunderabad 7001305949 all area service COD available Any TimeCall Girls Secunderabad 7001305949 all area service COD available Any Time
Call Girls Secunderabad 7001305949 all area service COD available Any Timedelhimodelshub1
 
Russian Escorts Delhi | 9711199171 | all area service available
Russian Escorts Delhi | 9711199171 | all area service availableRussian Escorts Delhi | 9711199171 | all area service available
Russian Escorts Delhi | 9711199171 | all area service availablesandeepkumar69420
 
Call Girls Hyderabad Krisha 9907093804 Independent Escort Service Hyderabad
Call Girls Hyderabad Krisha 9907093804 Independent Escort Service HyderabadCall Girls Hyderabad Krisha 9907093804 Independent Escort Service Hyderabad
Call Girls Hyderabad Krisha 9907093804 Independent Escort Service Hyderabaddelhimodelshub1
 
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in LucknowRussian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknowgragteena
 
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...High Profile Call Girls Chandigarh Aarushi
 
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service DehradunDehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service DehradunNiamh verma
 

Recently uploaded (20)

Low Rate Call Girls In Bommanahalli Just Call 7001305949
Low Rate Call Girls In Bommanahalli Just Call 7001305949Low Rate Call Girls In Bommanahalli Just Call 7001305949
Low Rate Call Girls In Bommanahalli Just Call 7001305949
 
Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Saloni 9907093804 Independent Escort Service Hyd...
 
VIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service Hyderabad
VIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service HyderabadVIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service Hyderabad
VIP Call Girls Hyderabad Megha 9907093804 Independent Escort Service Hyderabad
 
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
 
Call Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service Mohali
Call Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service MohaliCall Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service Mohali
Call Girls in Mohali Surbhi ❤️🍑 9907093804 👄🫦 Independent Escort Service Mohali
 
Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...
Russian Call Girls Hyderabad Indira 9907093804 Independent Escort Service Hyd...
 
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
 
Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...
Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...
Russian Call Girls in Hyderabad Ishita 9907093804 Independent Escort Service ...
 
Russian Call Girls in Raipur 9873940964 Book Hot And Sexy Girls
Russian Call Girls in Raipur 9873940964 Book Hot And Sexy GirlsRussian Call Girls in Raipur 9873940964 Book Hot And Sexy Girls
Russian Call Girls in Raipur 9873940964 Book Hot And Sexy Girls
 
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
 
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
 
hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...
hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...
hyderabad call girl.pdfRussian Call Girls in Hyderabad Amrita 9907093804 Inde...
 
Call Girls Secunderabad 7001305949 all area service COD available Any Time
Call Girls Secunderabad 7001305949 all area service COD available Any TimeCall Girls Secunderabad 7001305949 all area service COD available Any Time
Call Girls Secunderabad 7001305949 all area service COD available Any Time
 
Russian Escorts Delhi | 9711199171 | all area service available
Russian Escorts Delhi | 9711199171 | all area service availableRussian Escorts Delhi | 9711199171 | all area service available
Russian Escorts Delhi | 9711199171 | all area service available
 
Call Girls Hyderabad Krisha 9907093804 Independent Escort Service Hyderabad
Call Girls Hyderabad Krisha 9907093804 Independent Escort Service HyderabadCall Girls Hyderabad Krisha 9907093804 Independent Escort Service Hyderabad
Call Girls Hyderabad Krisha 9907093804 Independent Escort Service Hyderabad
 
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in LucknowRussian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
 
College Call Girls Dehradun Kavya 🔝 7001305949 🔝 📍 Independent Escort Service...
College Call Girls Dehradun Kavya 🔝 7001305949 🔝 📍 Independent Escort Service...College Call Girls Dehradun Kavya 🔝 7001305949 🔝 📍 Independent Escort Service...
College Call Girls Dehradun Kavya 🔝 7001305949 🔝 📍 Independent Escort Service...
 
Russian Call Girls South Delhi 9711199171 discount on your booking
Russian Call Girls South Delhi 9711199171 discount on your bookingRussian Call Girls South Delhi 9711199171 discount on your booking
Russian Call Girls South Delhi 9711199171 discount on your booking
 
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
 
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service DehradunDehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
 

Exploring Intensified Seed Train Through Advancements in Perfusion Processing Technologies

  • 1. MerckMillipore.com The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 VCD,e6cells/mL Culture Age, days ATF-6, 20 L ATF-6, 40 L Cellicon TFF, 50 L (1) Cellicon TFF, 50 L (2) Cellicon™ TFF Filter, 50 L (1) Cellicon™ TFF Filter, 50 L (2) 0 50 100 150 200 0 5 10 15 20 0 1 2 3 4 5 6 7 8 9 10 kLa,hr-1 Measuredin1XPBS,55W/m3 Total Gas Flow, L / min ActualVCD(e6c/mL) ModeledMaxVCD(e6c/mL) model-predicted max VCD capability with this cell line ~150 e6 c/mL OUR = OTR VCD x qO2 = kLa x (C* - CL) Introduction With recent advancements in media development and cell retention technologies, perfusion processes are rapidly emerging as a viable means to successfully intensify upstream biomanufacturing operations. The fresh supply of key nutrients coupled with the removal of waste products while retaining the thriving cell culture in the bioreactor can lead to higher accumulated cell densities, improved viabilities, and greater volumetric productivities. These process advancements can translate to savings in time, footprint, and/or cost in the manufacturing space. In this poster we explore key elements of the bioreactor design and automation strategies that enable the successful implementation of seed train intensification via perfusion. Sparger performance characterization, cell retention device connection, and evaluation of the Hamilton® Incyte viable cell density (or permittivity) sensor are specifically explored. Cell culture case studies are also presented to demonstrate the effectiveness of using the Mobius® single-use bioreactor for intensified seed train applications. Perfused N-1 CoGS Assessment A comprehensive cost modeling assessment was performed to examine more closely how specific production scenarios can be impacted by implementing a perfused N-1 process step followed by a fed-batch N (production). Figure 1 below highlights a subset of the data generated. Figure 1 Assumptions: • 1 Seed Train - 1 Production bioreactor - 1 DSP • 200 L N-1 bioreactor • 2000 L Production bioreactor (X0=5 x106 cells/mL) • 14 day production for both traditional and high seed • Industry average costs Figure 1: CoGS, throughput, and batches/year are compared for various scenarios of increasing production titer. The increase in titer results when a perfused N-1 process enables a high- seed fed-batch production. Four of the five scenarios assume the production is carried out for a comparable number of days compared to the traditional fed-batch process (14 days), and a fifth scenario (bar 2) examines the impact of perfused N-1 enabling a high-seed production reactor to achieve comparable titer to the traditional process but within a shorter duration of 10 days. For more information watch the on demand webinar: A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Process Modeling Anne Hansen, Allyson Fournier, Alison Dupont, Marisa Maher, Hiral Gami, Habib Horry, Jeffrey Barna, Arshan Nazempour, Amy Wood Merck Hamilton® Incyte VCD Sensor Exploration The capability to incorporate new sensor technology such as viable cell density (or permittivity) into recipes and PID control loops may help to advance perfusion processing operations. Figures 5, 6 and 7 explore how a VCD sensor can be used in perfusion processes in the Mobius® single-use bioreactors. Figures 5 & 6: Offline VCD data is plotted with InCyte sensor permittivity data for the growth phase of 4x 3L and 2x 50 L trials (Figure 5, top). When plotted on an x-y scatter, the slope of the linear fit line gives a cell factor of 1.45 (Figure 6, bottom). Using the offset value from the cell free media “zero” prior to inoculation, the 1.45 cell factor was applied retrospectively to the data collected during the 2nd 50 L trial, and plotted as InCyte VCD in Figures 5 and 7 below. This historical correlation model, using a single cell factor, showed strong correlation between offline and inline VCD. Figure 7: Implementing CSPR control (cell specific perfusion rate, purple) during a 50 L N-1 perfusion process using the Hamilton® InCyte VCD Sensor provided a steady ratio of nutrients to cells, drove towards more consistent cell culture conditions, and enabled a better estimate of media usage. Note, CSPR control was not implemented until the second day of perfusion (day 4 of process), due to the limited ability for the pump to operate in a continuous mode at low speeds. Operating the harvest pump in on/off mode is not recommended due to potential negative impact on CRD performance. Cell Culture & Sparger Performance Results • 4 N-1 perfusion trials were performed with ring sparger prototype flexware; 2 with Xcell™ ATF devices, 2 with prototype Cellicon™ 50 L filters (operating in TFF mode) • The 4 processes demonstrate consistent capability to support VCDs of at least 50-90 e6 c/mL with the ring sparger • Using the real-time gas flow rates and corresponding VCD data from a cell culture trial, the specific oxygen uptake rate, qO2, can be calculated. Together with measured kLa, the maximum VCD that the system can support can be modeled. In the example shown in Figure 4, using pure O2 and 55 W/m3, the system is expected to be able to support sustaining up to 150 e6 c/mL with this cell line Exploring Intensified Seed Train Through Advancements in Perfusion Processing Technologies © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, Millipore, Cellicon, Mobius and the vibrant M are trademarks, and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. MK_PS6000EN V.1.0 Incyte VCD Sensor Exploration Results • As shown in the 2nd 50 L trial in Figures 5 and 7, the offline VCD had a strong correlation to the InCyte sensor VCD during the growth phase of this process when using the historical correlation model. • This approach was successful during the growth phase of a culture up to ~ 50 e6 c/mL • Adjustments to the cell factor are likely to be needed to maintain a strong correlation if higher densities and/or subsequent culture phases occur in the process. 0 20 40 60 80 100 120 140 0 10 20 30 40 50 60 70 0 1 2 3 4 5 6 HarvestRate,L/day VCD,e6cells/mL Weight,kg CSPR,pL/cell.day Culture Age, Days InCyte VCD Offline VCD y = 1,4479x - 0,7763 R² = 0,9773 0 10 20 30 40 50 60 70 80 90 100 0 10 20 30 40 50 60 70 e6cells/mL pF/cm Offline VCD Linear (Offline VCD) 0 10 20 30 40 50 60 70 80 90 100 3456789 01234567 12345 2345678 012345 0123456 pF/cm e6cells/mL Culture Age, days Permittivity (pF/cm) Offline VCD InCyte VCD 50L Trials3L Trials 4 5 NEW: entirely flexible film construction @ bag base NEW: 2 x ¾” AseptiQuik® Connectors to install cell retention technologies 2 NEW: Ability to include CO2 sensor with control loop and use additional spare sensor in PID control loops (ex: Capacitance / VCD sensor for cell bleed or CSPR control) 1 NEW: Built-in X-baffle; promotes homogeneous mixing and consistency across scales 5 4 6 NEW: load cell control loop 3 NEW: Ring sparger option • Implementing a perfused N-1 operation can directly translate to an improvement in throughput and/or reduction in CoGS • Decreased process duration, made possible by perfused seed train operations, allows for more batches per year • Development of a high-seed fed-batch production process, enabled by the perfused N-1 operation, is a potential way to improve overall titer, drive down costs, and improve throughput without the need of additional batches or volume capacity • Perfusion seed train operations can prove to be an effective method of process intensification, while keeping the production bioreactor operating in fed- batch mode CoGS Assessment Results Bioreactor Advancements Supporting Perfusion Several upgrades have been made to the 50 and 200 L Mobius® single-use bioreactors in order to meet the needs of perfused N-1 processes; refer to Figure 2 below. Figure 2: Key features in Mobius® 50 and 200 L single-use bioreactors targeted to support perfused N-1 processes Cell Culture and Sparger Performance Results Four N-1 perfusion process trials were conducted in prototype flexware bags containing the ring sparger to assess performance. Both ATF and TFF type CRDs were used. Figure 3: Several trials confirm that the Mobius® bioreactor system is capable of supporting upwards of 50 e6 c/mL, with a max of 90 e6 c/mL realized using a 50 L prototype of the Cellicon™ TFF filter (green). Although the ring sparger was used in all 4 cases, two different cell lines were used and process conditions were varied by design, therefore identical performance was not expected across the trials. Figure 4: A model predicted capability to support a max VCD of 150 e6 c/mL (pink) was determined based on measured kLa (purple), real-time gas profiles (not shown), and VCD obtained during trial (blue)